Quick Answer
Phathom Pharmaceuticals, Inc. reported Cash and Equivalents of $129.97 million for fiscal year 2025.
Phathom Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $129.97M | -56.3% |
| 2024 | $297.26M | -22.1% |
| 2023 | $381.39M | +145.5% |
| 2022 | $155.38M | -15.2% |
| 2021 | $183.26M | -36.3% |
| 2020 | $287.50M | +17.9% |
| 2019 | $243.76M | +27632.1% |
| 2018 | $879.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $135.16M | -59.6% | -9.6% |
| June 30, 2025 | $149.57M | -45.9% | -29.6% |
| March 31, 2025 | $212.31M | -34.1% | -28.6% |
| December 31, 2024 | $297.26M | -22.1% | -11.2% |
| September 30, 2024 | $334.68M | +56.6% | +21.2% |
| June 30, 2024 | $276.24M | +11.0% | -14.3% |
| March 31, 2024 | $322.23M | +148.7% | -15.5% |
| December 31, 2023 | $381.39M | +145.5% | +78.5% |
- Phathom Pharmaceuticals, Inc. showed a decrease of -56.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Phathom Pharmaceuticals, Inc.’s cash and equivalents has grown by 14686.3% (from $879.0 thousand to $129.97 million).
- The most recent figure is from Phathom Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: